GSK PLC (LSE:GSK, NYSE:GSK) has received a second dose of good news this week that augers well for the roll-out of its respiratory syncytial virus (RSV) jab.
An advisory committee to the US Centers for Disease Control and Prevention (CDC) has recommended that adults aged 60 and over consider a single dose of GSK or rival Pfizer's RSV vaccine.
The advice follows stellar results from a phase III trial of the UK drug group's inoculation, which showed it lasted over two seasons.
RSV causes cold-like symptoms but can be severe in older adults and children. Each year, it results in 6,000 to 10,000 deaths among the elderly.
.